Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma - Findings from the PRACTICAL study, a randomized clinical trial
European Respiratory Journal Feb 15, 2020
Baggott C, Reddel HK, Hardy J, et al. - In the 2019 update of the Global Initiative for Asthma (GINA), symptom-driven low-dose inhaled corticosteroid-formoterol has been recommended as one of the preferred treatment regimens at steps 1 and 2, researchers here sought for data on patient preferences for this regimen. They assessed a subgroup of participants in the PRACTICAL study, a randomized control trial comparing symptom-driven budesonide-formoterol with maintenance budesonide plus as-needed terbutaline, via surveying them on treatment preferences, satisfaction, beliefs and experience at their final study visit. The survey was completed by 306 of 407 eligible participants (75%). Observations revealed that most participants preferred the regimen to which they had been randomized, however, those randomized to budesonide-formoterol as needed exhibited this association much strongly, intimating that most patients favored as-needed corticosteroid-formoterol therapy if they had undergone it.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries